Tina Kocher
Family · Granger, INNPI 1508105818
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $726 of the $925 with a category attached, or 78.5%. It is spread thinly across 25 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $587 and has fallen 94.4% since, to $33 in 2024.
Across 44 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$129
- Astellas Pharma US Inc$99
- AstraZeneca$87
- Amgen$78
- Novartis$75
- AbbVie$64
- plus $395 from 19 others
Across 6 payments — averaging $4783.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$29K
What the payments were for
- Food & beverage$72678%
- Education$19922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 3 | $129 |
| Astellas Pharma US Inc | 1 | $99 |
| AstraZeneca | 5 | $87 |
| Amgen | 5 | $78 |
| Novartis | 4 | $75 |
| AbbVie | 2 | $64 |
| Incyte Corporation | 3 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Johnson & Johnson(2 entities) | 2 | $30 |
| Pfizer | 2 | $26 |
| G1 Therapeutics, Inc. | 1 | $23 |
| Bayer | 1 | $22 |
| Eisai Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| GSK | 1 | $19 |
| Sanofi | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Tolmar Pharmaceuticals, Inc. | 1 | $16 |
| Gilead | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Morphosys, US Inc. | 1 | $15 |
| Myovant Sciences Inc. | 1 | $15 |
| Dova Pharmaceuticals | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
How this compares
$925 in reported general payments places this provider in the 65th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 20 | $228 |
Paid to pharmacies, not to this prescriber.
Other family in Granger
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.